| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
|
| Targets |
STING[1][2][3][4].
|
|---|---|
| ln Vitro |
Human colon cancer cells cannot proliferate when exposed to cyclic-di-GMP disodium (0.5-50 μM; 5 days)[1]. ?In Jurkat cells, cyclic-di-GMP disodium (0.5-50 μM; 5 days) selectively increases CD4 expression[2]. ?In Jurkat cells, cyclic-di-GMP disodium (0.5-50 μM; 5 days) causes cell cycle arrest at the S-phase[2].
|
| ln Vivo |
The administration of two consecutive vaccinations, separated by nine days, with 100 μg/per of cyclic-di-GMP disodium (iv) improves the immune responses TriVax elicits in mice against melanoma and amplifies its anti-tumor effects[3].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: H508 cells Tested Concentrations: 0.5- 50 µM Incubation Duration: 5 days Experimental Results: diminished basal H508 cell proliferation by approx 15%, even inhibited acetylcholine- and EGF-induced cell proliferation. Cell Viability Assay[2] Cell Types: Jurkat cells Tested Concentrations: 50 µM Incubation Duration: 24 h Experimental Results: Specifically induced of CD4 (no effect on the expression of CD8), with a 6.3-fold upregulation over control and in a dose-dependent manner. Cell Cycle Analysis[2] Cell Types: Jurkat cells Tested Concentrations: 50 µM Incubation Duration: 24 h Experimental Results: Increased the percentage of cells in S-phase by 79%, with almost complete disappearance of G2/M-phase cells which diminished by 93%. |
| Animal Protocol |
Animal/Disease Models: C57BL/ 6 (B6) mice (8- to 10weeks old)[3].
Doses: 100 µg/per Route of Administration: intravenous (iv) injection; two sequential vaccinations 9 days apart; combine with TriVax. Experimental Results: Dramatically higher numbers of antigen-specific CD8 T cells when combined with TriVax. (TriVax consisted of a mixture of 120 μg Pam-hgp100, 100 μg hgp100 or 100 μg Ova, 50 or 25 μg anti-CD40 antibody, and 25 μg Poly-IC). Enhanced the anti- tumor activity of TriVax. |
| References |
| Molecular Formula |
C20H25N10NAO14P2
|
|---|---|
| Molecular Weight |
714.408395528793
|
| Exact Mass |
734.058
|
| CAS # |
2222132-40-1
|
| Related CAS # |
Cyclic-di-GMP diammonium;609343-82-0;Cyclic-di-GMP;61093-23-0;Cyclic-di-GMP sodium
|
| PubChem CID |
137120247
|
| Appearance |
Off-white to light yellow solid powder
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
48
|
| Complexity |
1320
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
O=C1N=C(N)NC2N([C@@H]3O[C@]4([H])COP(O[C@@]5([H])[C@@H](O)[C@H](N6C=NC7C(N=C(N)NC6=7)=O)O[C@]5([H])COP(O)(=O)O[C@@]4([H])[C@H]3O)(O)=O)C=NC1=2.[NaH]
|
| InChi Key |
SVIXOIGPVFFABR-XDODWTFASA-L
|
| InChi Code |
InChI=1S/C20H24N10O14P2.2Na/c21-19-25-13-7(15(33)27-19)23-3-29(13)17-9(31)11-5(41-17)1-39-45(35,36)44-12-6(2-40-46(37,38)43-11)42-18(10(12)32)30-4-24-8-14(30)26-20(22)28-16(8)34;;/h3-6,9-12,17-18,31-32H,1-2H2,(H,35,36)(H,37,38)(H3,21,25,27,33)(H3,22,26,28,34);;/q;2*+1/p-2/t5-,6-,9-,10-,11-,12-,17-,18-;;/m1../s1
|
| Chemical Name |
disodium;2-amino-9-[(1S,6R,8R,9R,10S,15R,17R,18R)-17-(2-amino-6-oxo-1H-purin-9-yl)-9,18-dihydroxy-3,12-dioxido-3,12-dioxo-2,4,7,11,13,16-hexaoxa-3λ5,12λ5-diphosphatricyclo[13.3.0.06,10]octadecan-8-yl]-1H-purin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 160 mg/mL (217.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 50 mg/mL (68.09 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3998 mL | 6.9988 mL | 13.9976 mL | |
| 5 mM | 0.2800 mL | 1.3998 mL | 2.7995 mL | |
| 10 mM | 0.1400 mL | 0.6999 mL | 1.3998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
